{"id":"seroquel-and-risperidone","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Weight gain"},{"rate":"15-25","effect":"Sedation/somnolence"},{"rate":"10-20","effect":"Extrapyramidal symptoms (tremor, rigidity, akathisia)"},{"rate":"15-40","effect":"Prolactin elevation/hyperprolactinemia"},{"rate":"5-15","effect":"Orthostatic hypotension"},{"rate":"10-20","effect":"Metabolic syndrome/dyslipidemia"},{"rate":"5-15","effect":"Akathisia"}]},"_chembl":{"chemblId":"CHEMBL85","moleculeType":"Small molecule","molecularWeight":"410.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Seroquel (quetiapine) and Risperidone are second-generation antipsychotics that antagonize dopamine D2 and serotonin 5-HT2A receptors, with additional activity at other serotonergic and adrenergic receptors. By blocking these neurotransmitter pathways, they reduce positive symptoms (hallucinations, delusions) and negative symptoms of psychosis, and are also used for mood stabilization in bipolar disorder. Risperidone has higher D2 receptor affinity and potency compared to quetiapine.","oneSentence":"Both drugs are atypical antipsychotics that block dopamine D2 receptors and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:07:34.217Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute mania and maintenance)"},{"name":"Irritability associated with autism spectrum disorder (risperidone)"},{"name":"Major depressive disorder (adjunctive, quetiapine)"}]},"trialDetails":[{"nctId":"NCT05741502","phase":"PHASE4","title":"An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine","status":"TERMINATED","sponsor":"Ohio State University","startDate":"2023-08-16","conditions":"Treatment-resistant Schizophrenia","enrollment":5},{"nctId":"NCT06581302","phase":"NA","title":"Magnetic Seizure Therapy for Psychotic Disorders","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-09-01","conditions":"Psychotic Disorders","enrollment":50},{"nctId":"NCT01246765","phase":"","title":"National Pregnancy Registry for Psychiatric Medications","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2008-11","conditions":"Pregnant Women, Psychotropic Drugs","enrollment":5000},{"nctId":"NCT02431702","phase":"PHASE3","title":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-08","conditions":"Schizophrenia, Psychotic Disorders","enrollment":337},{"nctId":"NCT02237417","phase":"PHASE4","title":"Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-01","conditions":"Schizophrenia","enrollment":47},{"nctId":"NCT02958800","phase":"NA","title":"Deprescribing Antipsychotics in Long-Term Care","status":"COMPLETED","sponsor":"McMaster University","startDate":"2016-12","conditions":"Dementia, Behavior","enrollment":6},{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT05402111","phase":"PHASE1","title":"A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-06-13","conditions":"Schizophrenia","enrollment":31},{"nctId":"NCT05542264","phase":"PHASE1","title":"A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-11-15","conditions":"Schizophrenia","enrollment":19},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT06200584","phase":"NA","title":"Synergistic Effect of Vitamin E & D in Reducing Risk of Effects Associated With Atypical Anti-psychotics","status":"COMPLETED","sponsor":"Dr Rabia Arshad","startDate":"2021-01-01","conditions":"Antipsychotics and Neuroleptics Toxicity","enrollment":140},{"nctId":"NCT04312503","phase":"","title":"Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia\"","status":"COMPLETED","sponsor":"Aziende Chimiche Riunite Angelini Francesco S.p.A","startDate":"2020-07-13","conditions":"Schizophrenia","enrollment":95},{"nctId":"NCT05833399","phase":"","title":"Correlation of Genetic Variations With Clinical Response in Substance Use Disorder","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-11-28","conditions":"Substance Use Disorders, Substance Dependence","enrollment":200},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT03019887","phase":"NA","title":"Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction","status":"COMPLETED","sponsor":"Juntendo University","startDate":"2011-04","conditions":"Schizophrenia Relapse","enrollment":139},{"nctId":"NCT00159770","phase":"PHASE3","title":"Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2001-11","conditions":"Schizophrenia, Schizoaffective Disorder, Psychotic Disorders","enrollment":290},{"nctId":"NCT04446234","phase":"PHASE4","title":"Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2021-05","conditions":"Schizophrenia","enrollment":350},{"nctId":"NCT03568500","phase":"PHASE4","title":"A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-05-21","conditions":"Schizophrenia, Schizoaffective Disorder, First Episode Psychosis","enrollment":44},{"nctId":"NCT03007303","phase":"","title":"The Relevance Between the microRNA-30e in Plasma and the Prognosis of Schizophrenia Patients","status":"UNKNOWN","sponsor":"Dalian Seventh People's Hospital","startDate":"2016-06","conditions":"Schizophrenia, Micrognathia","enrollment":30},{"nctId":"NCT00515723","phase":"NA","title":"Glucose and Lipid Metabolism on Antipsychotic Medication","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2001-09","conditions":"Schizophrenia, Schizoaffective Disorder, Type 2 Diabetes Mellitus","enrollment":96},{"nctId":"NCT00161018","phase":"PHASE3","title":"New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2003-11","conditions":"Schizophrenia","enrollment":150},{"nctId":"NCT02600741","phase":"","title":"Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-24","conditions":"Schizophrenia","enrollment":296},{"nctId":"NCT02307396","phase":"PHASE4","title":"Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-02-01","conditions":"Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders","enrollment":21},{"nctId":"NCT00509067","phase":"PHASE2","title":"Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2007-11","conditions":"Schizophrenia","enrollment":43},{"nctId":"NCT02051387","phase":"PHASE1","title":"Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study","status":"COMPLETED","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2013-01","conditions":"Schizophrenia","enrollment":74},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT00806234","phase":"PHASE4","title":"Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-01","conditions":"Psychotic Disorders","enrollment":127},{"nctId":"NCT02462473","phase":"PHASE2","title":"A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-05","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":9},{"nctId":"NCT02423096","phase":"","title":"Neuroendocrine and Metabolite Substrates in Schizophrenia","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2013-12","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT02192723","phase":"NA","title":"A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia","status":"COMPLETED","sponsor":"Beijing HuiLongGuan Hospital","startDate":"2012-06","conditions":"Schizophrenia","enrollment":550},{"nctId":"NCT01739127","phase":"","title":"Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2012-11","conditions":"Psychotic Disorders, Bipolar Disorder, Metabolic Syndrome X","enrollment":83},{"nctId":"NCT00177164","phase":"PHASE3","title":"Risperdal Consta for Bipolar Disorder","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2003-11","conditions":"Bipolar I Disorder","enrollment":50},{"nctId":"NCT01844700","phase":"PHASE4","title":"1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain","status":"TERMINATED","sponsor":"Northwell Health","startDate":"2013-07","conditions":"High Risk MC4R Genotype, Low Risk MC4R Genotype, One Week or Less Antipsychotic Lifetime Exposure","enrollment":14},{"nctId":"NCT02087579","phase":"PHASE1","title":"Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02","conditions":"Psychotic Disorders, Schizophrenia, Bipolar Disorder","enrollment":305},{"nctId":"NCT02582736","phase":"","title":"Antipsychotics and Risk of Hyperglycemic Emergencies","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2012-04","conditions":"Psychotic Disorders, Schizophrenia, Schizoaffective Disorder","enrollment":725489},{"nctId":"NCT01305707","phase":"PHASE4","title":"Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression","status":"TERMINATED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2009-07","conditions":"Depression","enrollment":104},{"nctId":"NCT02282085","phase":"PHASE4","title":"Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia","status":"UNKNOWN","sponsor":"Matt Byerly","startDate":"2014-12","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT01157351","phase":"PHASE4","title":"15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2010-05","conditions":"Schizophrenia","enrollment":450},{"nctId":"NCT01765829","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2012-11","conditions":"Psychosis Nos/Other","enrollment":104},{"nctId":"NCT00216476","phase":"PHASE3","title":"A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2004-10","conditions":"Schizophrenia, Psychotic Disorders","enrollment":753},{"nctId":"NCT00048802","phase":"PHASE4","title":"Treatment and Outcome of Early Onset Bipolar Disorder","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2002-08","conditions":"Bipolar Disorder","enrollment":40},{"nctId":"NCT00857818","phase":"PHASE3","title":"Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2009-04","conditions":"Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder","enrollment":64},{"nctId":"NCT00237913","phase":"PHASE3","title":"Schizophrenia Trial of Aripiprazole","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-07","conditions":"Schizophrenia","enrollment":700},{"nctId":"NCT01193166","phase":"PHASE4","title":"Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital","status":"WITHDRAWN","sponsor":"Ortho-McNeil Janssen Scientific Affairs, LLC","startDate":"2010-08","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT00182013","phase":"PHASE4","title":"Open-Label Comparative Study of Risperidone Versus Olanzapine Versus Quetiapine for Mania in Children and Adolescents With Bipolar I and Bipolar II Disorder","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2001-06","conditions":"Bipolar Spectrum Disorder","enrollment":106},{"nctId":"NCT01607762","phase":"PHASE1","title":"A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-02","conditions":"Healthy","enrollment":31},{"nctId":"NCT01129674","phase":"PHASE2, PHASE3","title":"A Long-Term, Open-Label, Study on Schizophrenia","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2010-06","conditions":"Schizophrenia","enrollment":1210},{"nctId":"NCT00206102","phase":"PHASE4","title":"A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-09","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":1098},{"nctId":"NCT00600756","phase":"PHASE3","title":"Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-01","conditions":"Schizophrenic Disorders","enrollment":798},{"nctId":"NCT00640562","phase":"PHASE3","title":"Quetiapine Extended Release Depression Symptoms","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-02","conditions":"Schizophrenia, Depression","enrollment":216},{"nctId":"NCT01272765","phase":"PHASE2","title":"Anti-psychotic Medication (Stable Dose) Weight Loss Study","status":"WITHDRAWN","sponsor":"Avera McKennan Hospital & University Health Center","startDate":"2012-03","conditions":"Obesity","enrollment":""},{"nctId":"NCT01272752","phase":"PHASE2","title":"Anti-psychotic Medication (New Use) Weight Loss Study","status":"WITHDRAWN","sponsor":"Avera McKennan Hospital & University Health Center","startDate":"2013-04","conditions":"Obesity","enrollment":""},{"nctId":"NCT00061802","phase":"PHASE4","title":"Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2003-06","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":225},{"nctId":"NCT00097032","phase":"PHASE3","title":"Study Measuring Differences in Cognition Due to Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Outpatients","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-10","conditions":"Bipolar Disorder","enrollment":30},{"nctId":"NCT00817648","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Seroquel in Chinese Han Patients With Schizophrenia","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2008-12","conditions":"Schizophrenia","enrollment":120},{"nctId":"NCT00932529","phase":"PHASE4","title":"Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting","status":"COMPLETED","sponsor":"University of Bergen","startDate":"2003-02","conditions":"Psychotic Disorders","enrollment":226},{"nctId":"NCT00304616","phase":"PHASE4","title":"SWitching to Abilify Trial (SWAT)","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2004-10","conditions":"Schizophrenia","enrollment":500},{"nctId":"NCT01016145","phase":"PHASE4","title":"Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2009-04","conditions":"Schizophrenia or Schizoaffective Disorder","enrollment":126},{"nctId":"NCT00254241","phase":"PHASE4","title":"Safety and Efficacy of Seroquel in First Episode Schizophrenia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-05","conditions":"Schizophrenia","enrollment":80},{"nctId":"NCT00305422","phase":"PHASE3","title":"Effect of Quetiapine on Negative Symptoms and Cognition","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2001-11","conditions":"Schizophrenia","enrollment":45},{"nctId":"NCT00493233","phase":"NA","title":"Antipsychotic Polypharmacy in Schizophrenia","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2006-11","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT00498004","phase":"PHASE4","title":"Quality of Life (QOL) in Female Patient With Schizophrenia","status":"TERMINATED","sponsor":"Inje University","startDate":"2007-08","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT00347425","phase":"PHASE3","title":"Switch Study of Existing Atypical Antipsychotics to Bifeprunox","status":"COMPLETED","sponsor":"Solvay Pharmaceuticals","startDate":"2006-12","conditions":"Schizophrenia and Schizoaffective Disorder","enrollment":286},{"nctId":"NCT00654576","phase":"PHASE4","title":"Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia","status":"COMPLETED","sponsor":"Central South University","startDate":"2005-02","conditions":"Schizophrenia","enrollment":1400},{"nctId":"NCT00528359","phase":"","title":"β-Cell Function in Schizophrenic Subjects on Atypical Antipsychotic drugS","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2005-10","conditions":"Schizophrenia","enrollment":36},{"nctId":"NCT00208143","phase":"PHASE4","title":"Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia","status":"COMPLETED","sponsor":"Creighton University","startDate":"2003-11","conditions":"Schizophrenia, Schizoaffective Disorder, Substance Abuse","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Seroquel and Risperidone","genericName":"Seroquel and Risperidone","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Both drugs are atypical antipsychotics that block dopamine D2 receptors and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Irritability associated with autism spectrum disorder (risperidone).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}